Lanthio Pharma Raises €4.8 Million In Series A, Enters MorphoSys Pact
This article was originally published in The Pink Sheet Daily
Executive Summary
Dutch biotech Lanthio Pharma has entered into an alliance with MorphoSys to develop its lantipeptide technology, with the German drug-discovery company also participating in Lanthio Pharma’s Series A funding round.
You may also be interested in...
Dezima Pharma Raises $18.6 Million For Next-Generation CETP Inhibitor
Dutch start-up Dezima Pharma raises $18.6 million in Series A funding and government loans to move a next-generation CETP inhibitor to Phase III.
Financings Of The Fortnight: Can Crowdfunding Help Fill The Life Sciences Venture Gap?
Plus recent news on BioTime, Lanthio, Applied Genetics Technology, and TauRx.
Roche Partners With Peptide Specialist Aileron For Five Targets
A $25 million upfront commitment could blossom into a deal worth as much as $1.1 billion plus royalties.